Ista Pharmaceuticals Inc

Ista Pharmaceuticals — Investor Presentation (August 2011)

23 slides from Ista Pharmaceuticals's investor presentation, Aug 8, 2011

  1. Slide 1: Lauren Silvernail, CFO and VP Corporate Development

    Exhibit 99.1 Lauren Silvernail CFOandVPCorporateDevelopment

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied

  3. Slide 3: Company Timeline

    Company Timeline BROMDAY™ XIBROM™ BEPREVE® ISTALOL® VITRASE® 1992 2000 2002 2004 2005 2009 2010 Acquired ISTALOL & XIBROM Revenue ISTA >$100 million Profitable* Name change to ISTA Pharmaceuticals, Inc. IPO on NASDAQ“ISTA” – Founded as Advanced Corneal Systems * On an adjusted cash net income basis

  4. Slide 4: ISTA's Track Record of Success

    ISTA’s Track Record of Success • Obtained 5 Rx product approvals in 6 years – ISTALOL®, VITRASE®, XIBROM™, BEPREVE®, BROMDAY™ • Attained top market share positions • Built deep new product R&D pipeline • Assembled experienced management team, formidable specialty sales force: ~ 330 employees • Conve

  5. Slide 5: First Half Revenue Results

    First Half Revenue Results 1H ’11 1H ’10 % BROMDAY/XIBROM $36.6 $41.4 (12%) BEPREVE $16.4 $ 6.7 145% ISTALOL $14.2 $ 9.7 46% VITRASE $ 6.7 $ 5.6 20% NET REVENUES $73.9 $63.4 17% Trackingto ourguidance:40%1st half/ 60%2 nd halfof year ISTA PHARMACEUTICALS 5

  6. Slide 6: Fast-Growing, Niche Pharmaceutical Company

    ISTA Fast-Growing, Niche Pharmaceutical Company Net Revenues Outlook$175–$190 (in $millions) $157 $111 $83 $59 2007 2008 2009 2010 2011(F) ISTA PHARMACEUTICALS

  7. Slide 7: ISTA's 2011 Financial Guidance

    ISTA’s 2011 Financial Guidance 2011 Net Revenues $175 -$190 million Gross Margin* 75% -77% R&D* 18% -22% SG&A* 44% -48% Operating Income $13 -$16 million Adjusted Cash Net Income** $13 -$16 million Adjusted Cash EPS** (50 mm shares) $0.26 –$0.32 per share Cash at 12/31/11*** $80 -$90 million Growing

  8. Slide 8: Key Financial Notes for 2011

    Key Financial Notes for 2011 • Impact of healthcare reform: revenues $3m-$5m lower • Tax Rate: 2%-5% based on utilization of net loss carry forwards • Warrants reduced by 8.1 million of 15 million shares in first half • Debt: First of three annual ~$21 million principal repayments made August 2011 f

  9. Slide 9: BROMDAY Once-Daily

    BROMDAY™ Once-Daily (bromfenac ophthalmic solution) 0.09% • First and only approved once-daily Rx NSAID – For postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction • Rapid, successful switch from twice-daily XIBROM™ • Fast-growing, market-leading

  10. Slide 10: BROMDAY First Half Results

    BROMDAY First Half Results • Prescriptions (TRx) up 6.5%; revenues down 12% over first half ‘10 • Why? – Impact from XIBROM to BROMDAY conversion • Lower average price per script due to single, smaller bottle size • Lower refill rate for newly launched product • Wholesalers moderated BROMDAY invento

  11. Slide 11: BROMDAY Outlook Strong

    BROMDAY Outlook Strong Scripts Continue to Grow • Continuing to build NRx and TRx share on a weekly basis • Sales force re-focused on BROMDAY post-allergy season • Generic to XIBROM stalled at ~3% market share BROMDAY • Major new managedcareaccountwin – effectiveJuly1 WEEKLY MARKET SHARE • Planning

  12. Slide 12: BEPREVE

    BEPREVE ® (bepotastine besilate ophthalmic solution) 1.5% • For ocular itching associated with allergic conjunctivitis U.S. Prescription Allergy Eye Competitors • Launched Oct 2009 NRx$$ 6/30/11 • $16 million revenues in 2010 Lastacaft BEPREVE 2% 7% • Estimated 2011 U.S. market Elestat 1% value: $74

  13. Slide 13: BEPREVE YTD Prescription Growth Strong

    BEPREVE ® YTD Prescription Growth Strong BEPREVE TRx Peak Allergy • YTD June ‘11 TRx up 114%, TRx $$ up 195%. Season 35,000 Market share growth from 1.6% to 3.8%. • In its target audience, BEPREVE has 9.8% share. 30,000 • An Rx of BEPREVE generates between 35-60% more revenues than its competitors b

  14. Slide 14: Currently Approved Products Can Drive ISTA to >$300 Million in Annual Revenues

    Currently Approved Products Can Drive ISTA to >$300 Million in Annual Revenues BROMDAY™ BEPREVE® Once-daily prescription eye Twice-daily prescription drop for postoperative eye drop for ocular inflammation and itching associated with reduction of ocular pain in allergic conjunctivitis patients who h

  15. Slide 15: ISTA's Near-Term Pipeline

    ISTA’s Near-Term Pipeline Key Approvals Can Take Revenue to $500 million by 2015 Candidates* Formulation Phase 1 Phase 2 Phase 3 NDA Low-concentration Ocular Inflammation & Pain BROMDAY™ REMURA™ Dry Eye (bromfenac for dry eye) Bepotastine Nasal Allergic Rhinitis Bepotastine Nasal/Combo Antihistamine

  16. Slide 16: Active Pipeline Summary

    Active Pipeline Summary Current 2015 Market Exclusivity Drug Candidate Active Ingredient Rx Indication Stage/Status Potential Low-concentration Lower Inflammation & Initiated Phase 3 $400 MM 3-year Hatch BROMDAY™ concentration, pain post cataract study, Waxman. Pending new formulation surgery prelim

  17. Slide 17: Low-Concentration BROMDAY

    Low-Concentration BROMDAY™ Phase 3 Efficacy Studies Initiated May 2011 • Two Studies: East/West, 400 patients, 40 sites – 1x daily for 16 days – 1 dose prior to surgery, 1 dose day of surgery, 1 dose per day for 14 days • Primary outcome: cleared ocular inflammation – Defined as summed ocular inflam

  18. Slide 18: REMURA for Dry Eye

    REMURA™ for Dry Eye Underserved, $700 million market in 2011 • Targets inflammatory component • Future market potential >$2 billion • Strong Phase 2 results (at right) – 70% of patients responded – 30% reduction in ocular surface disease index (OSDI) • Two Phase 3 efficacy studies Baseline – ~1,000

  19. Slide 19: Bepotastine Nasal Spray

    Bepotastine Nasal Spray Positive Phase 2 Study Results, April 2011 • 600 patients, multi-sites in Texas – Patients presenting allergic rhinitis caused by Mountain Cedar Pollen • 3 concentrations dosed 2x day for 14 days – Patients graded both individual nasal and ocular symptoms on a daily basis • P

  20. Slide 20: ISTA: Strategy for Long-Term Success

    ISTA: Strategy for Long-Term Success Marketed Product Business Products Pipeline Development • Low-concentration • Acquire marketed products BROMDAY™ • License late stage (Phase 3) Rx Eye • REMURA™ for dry eye • T-PRED™ • Strong steroid • Bepotastine • Acquire marketed products Rx Allergy & - Nasal

  21. Slide 21: ISTA's 2011 Milestones to Drive Shareholder Value

    ISTA's 2011 Milestones to Drive Shareholder Value Product / Candidates Milestone Timing BROMDAY once-daily Complete switch from XIBROM DONE Q1 Low-concentration BROMDAY Initiate Phase 3 Done Q2 for inflammation and pain assoc with cataract extraction Prelim Phase 3 results Q4 Prelim Phase 3 efficacy

  22. Slide 22: ISTA's Strategic Vision "5 in 5"

    ISTA’s Strategic Vision “5 in 5” • Become one of top 3 branded Rx eye care companies in the U.S. • Achieve #1 or #2 position in each product market • Deliver EPS* of $1.00 by 2013 (based on 50 million shares) • Generate $500 million in revenue in 5 years – Develop products for larger markets • Obtai

  23. Slide 23: ] A Pharmaceuticals”

    ] A Pharmaceuticals” IS

Ista Pharmaceuticals — Investor Presentation (August 2011) on 6ix